ImmunoPrecise Antibodies (IPA) Expected to Announce Quarterly Earnings on Tuesday

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) is projected to release its Q4 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect ImmunoPrecise Antibodies to post earnings of ($0.02) per share and revenue of $7.89 million for the quarter.

ImmunoPrecise Antibodies Trading Down 2.9%

Shares of IPA traded down $0.05 during mid-day trading on Tuesday, hitting $1.70. The company's stock had a trading volume of 745,446 shares, compared to its average volume of 2,635,866. ImmunoPrecise Antibodies has a 1-year low of $0.27 and a 1-year high of $2.32. The company has a quick ratio of 2.11, a current ratio of 2.32 and a debt-to-equity ratio of 0.45. The firm has a 50-day simple moving average of $0.95 and a 200 day simple moving average of $0.62.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on IPA shares. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of ImmunoPrecise Antibodies in a research note on Friday, April 11th. Benchmark restated a "speculative buy" rating and issued a $3.00 price target on shares of ImmunoPrecise Antibodies in a report on Tuesday, April 1st. Finally, Wall Street Zen raised shares of ImmunoPrecise Antibodies to a "sell" rating in a research note on Saturday, May 24th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.